The DOI matches its Crossref record; 129 of the 129 references it cites were found in a registry or an index.
Guidelines for the Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group
Abstract
Dyslipidemia is a common problem affecting HIV-infected patients receiving antiretroviral therapy. Since publication of preliminary guidelines in 2000 [1], numerous studies have addressed the risk of cardiovascular disease, the mechanisms of dyslipidemia, drug interactions, and the treatment of lipid disorders in HIV-infected patients. In addition, updated recommendations from the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III [ATP III]) have been published [2] that materially affect the clinical approach to lipid disorders in the general population. A working group of clinical scientists, consisting of members of the Cardiovascular Subcommittee of the AIDS Clinical Trials Group, updated the preliminary recommendations to assist clinicians in the evaluation and treatment of lipid disorders among HIV-infected adults. Data regarding the prevalence and incidence of dyslipidemia and cardiovascular disease in HIV-infected patients, pharmacokinetic profiles for hypolipidemic agents, and treatment trials of dyslipidemia in HIV-infected patients were considered. Although the implications of dyslipidemia in this population are not fully known, preliminary data indicate increased cardiovascular morbidity among HIV-infected individuals, suggesting that measures to reduce cardiovascular risk should be provided. We recommend that HIV-infected adults undergo evaluation and treatment on the basis of NCEP ATP III guidelines for dyslipidemia, with particular attention to potential drug interactions with antiretroviral agents and maintenance of virologic control of HIV infection. When drugs become necessary, we recommend as initial therapy pravastatin or atorvastatin for elevated low-density lipoprotein cholesterol levels and gemfibrozil or fenofibrate when triglyceride concentrations exceed 500 mg/dL. Cardiovascular disease and stroke are by far the leading causes of death and morbidity in the United States [3]. As the prognosis for HIV-infected persons steadily improves, these individuals will incur an increased risk for other major causes of morbidity and mortality, independent of any specific HIV- or treatment-related issue. Cardiovascular disease occurs earlier and at a higher rate in certain populations, such as black persons, that increasingly overlap with the epidemiology of HIV infection. It is reasonable to anticipate that this problem will worsen in the midst of the epidemic of obesity and diabetes in the United States [4] and elsewhere [5], an epidemic that disproportionately affects Hispanic and non-Hispanic black persons [6]. The close relationship between HIV care providers and their patients affords a major opportunity for primary and secondary prevention of non-HIV-related conditions, such as cardiovascular disease. These recommendations will assist the HIV clinician's efforts to broaden the health benefits associated with ongoing clinical care for adults in the HIV clinic. A comprehensive approach for evaluation and treatment of dyslipidemia in HIV-infected adults receiving antiretroviral therapy is outlined in figure 1. For particular recommendations and statements, the strength of the supporting evidence and quality of the data are rated by use of an Infectious Diseases Society of America-United States Public Health Service grading system [7] (table 1). A rating of A–E indicates the strength of a recommendation, and the Roman numerals I–III indicate the quality of the supporting evidence. These ratings are presented in parentheses after specific recommendations. General approach to lipid disorders and cardiovascular risk in HIV-infected patients receiving HAART. See text for additional explanation. CHD, coronary heart disease; HDL, high-density lipoprotein; LDL, low-density lipoprotein. Infectious Diseases Society of America-United States Public Health Service grading system for rating recommendations in clinical guidelines. Abnormalities of lipid metabolism in HIV-infected patients were described before the advent of HAART [8–13]. Increased serum triglyceride [8] and reduced total cholesterol [13] concentrations were associated with advanced HIV disease. Patients with AIDS have also had lower levels of high-density lipoprotein (HDL) cholesterol (HDL-C) and low-density lipoprotein (LDL) cholesterol (LDL-C), decreased triglyceride clearance, and a predominance of small, dense LDL particles, compared with controls [9, 11]. Therapy with zidovudine alone was associated with reduced cytokine activation and a decrease in serum triglyceride levels [14]. Protease inhibitors (PIs). Use of HIV PIs has been associated with hyperlipidemia that is more common and more severe than what was observed before the advent of HAART [1, 15–22]. Sixty-two (47%) of 133 PI recipients at one clinic [20] had lipid abnormalities that met the 1994 NCEP intervention criteria [23]. In the Swiss HIV Cohort, hypercholesterol
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001
Mokdad, A. H., Ford, E. S., Bowman, B. A., Dietz, W. H., Vinicor, F., Bales, V. S., & Marks, J. S. (2003) · JAMA · doi:10.1001/jama.289.1.76 · Cited by 5,866
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
Harris, M. I., Flegal, K. M., Cowie, C. C., Eberhardt, M. S., Goldstein, D. E., Little, R. R., Wiedmeyer, H.-M., & Byrd-Holt, D. D. (1998) · Diabetes Care · doi:10.2337/diacare.21.4.518 · Cited by 2,703
Carr, A., Samaras, K., Burton, S., Law, M., Freund, J., Chisholm, D. J., & Cooper, D. A. (1998) · AIDS · doi:10.1097/00002030-199807000-00003 · Cited by 2,370
Brown, B. G., Zhao, X.-Q., Chait, A., Fisher, L. D., Cheung, M. C., Morse, J. S., Dowdy, A. A., Marino, E. K., Bolson, E. L., Alaupovic, P., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011090 · Cited by 1,979
Grady, D., Herrington, D., Bittner, V., Blumenthal, R., Davidson, M., Hlatky, M., Hsia, J., Hulley, S., Herd, A., Khan, S., et al. (2002) · JAMA · doi:10.1001/jama.288.1.49 · Cited by 1,930
Carr, A., Samaras, K., Thorisdottir, A., Kaufmann, G. R., Chisholm, D. J., & Cooper, D. A. (1999) · The Lancet · doi:10.1016/s0140-6736(98)08468-2 · Cited by 1,495
Manninen, V, Tenkanen, L., Koskinen, P., Huttunen, J. K., Mänttäri, M., Heinonen, O. P., & Frick, M. H. (1992) · Circulation · doi:10.1161/01.cir.85.1.37 · Cited by 1,329
The Rising Prevalence of Diabetes and Impaired Glucose Tolerance
Dunstan, D. W., Zimmet, P. Z., Welborn, T. A., de Courten, M. P., Cameron, A. J., Sicree, R. A., Dwyer, T., Colagiuri, S., Jolley, D., Knuiman, M., et al. (2002) · Diabetes Care · doi:10.2337/diacare.25.5.829 · Cited by 907
Flexner, C. (1998) · New England Journal of Medicine · doi:10.1056/nejm199804303381808 · Cited by 852
Grunfeld, C. (1992) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.74.5.1045 · Cited by 848
Mitochondrial Myopathy Caused by Long-Term Zidovudine Therapy
Dalakas, M. C., Illa, I., Pezeshkpour, G. H., Laukaitis, J. P., Cohen, B., & Griffin, J. L. (1990) · New England Journal of Medicine · doi:10.1056/nejm199004193221602 · Cited by 844
Management of Dyslipidemia in Adults With Diabetes
Haffner, S. M. (1998) · Diabetes Care · doi:10.2337/diacare.21.1.160 · Cited by 786
Non–High-Density Lipoprotein Cholesterol Level as a Predictor of Cardiovascular Disease Mortality
Cui, Y., Blumenthal, R. S., Flaws, J. A., Whiteman, M. K., Langenberg, P., Bachorik, P. S., & Bush, T. L. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.11.1413 · Cited by 658
Lopinavir–Ritonavir versus Nelfinavir for the Initial Treatment of HIV Infection
Walmsley, S., Bernstein, B., King, M., Arribas, J., Beall, G., Ruane, P., Johnson, M., Johnson, D., Lalonde, R., Japour, A., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012354 · Cited by 647
Bozzette, S. A., Ake, C. F., Tam, H. K., Chang, S. W., & Louis, T. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022048 · Cited by 625
Atherogenic Dyslipidemia in HIV-Infected Individuals Treated With Protease Inhibitors
Périard, D., Telenti, A., Sudre, P., Cheseaux, J.-J., Halfon, P., Reymond, M. J., Marcovina, S. M., Glauser, M. P., Nicod, P., Darioli, R., et al. (1999) · Circulation · doi:10.1161/01.cir.100.7.700 · Cited by 605
Danner, S. A., Carr, A., Leonard, J. M., Lehman, L. M., Gudiol, F., Gonzales, J., Raventos, A., Rubio, R., Bouza, E., Pintado, V., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512073332303 · Cited by 567
Grundy, S. M. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.14.1568 · Cited by 551 · cited 1×
“of glycemia in diabetic subjects [100-102].”
Lennernäs, H., & Fager, G. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199732050-00005 · Cited by 527 · cited 1×
“Pravastatin, atorvastatin, and fluvastatin are administered directly as the active hydroxy-acid [135].”
Mulligan, K., Grunfeld, C., Tai, V. W., Algren, H., Pang, M., Chernoff, D. N., Lo, J. C., & Schambelan, M. (2000) · Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00042560-200001010-00005 · Cited by 518
Elam, M. B., Hunninghake, D. B., Davis, K. B., Garg, R., Johnson, C., Egan, D., Kostis, J. B., Sheps, D. S., Brinton, E. A., & for the ADMIT Investigators (2000) · JAMA · doi:10.1001/jama.284.10.1263 · Cited by 517
Behrens, G., Dejam, A., Schmidt, H., Balks, H.-J., Brabant, G., Körner, T., Stoll, M., & Schmidt, R. E. (1999) · AIDS · doi:10.1097/00002030-199907090-00001 · Cited by 515
Gagné, C., Bays, H. E., Weiss, S. R., Mata, P., Quinto, K., Melino, M., Cho, M., Musliner, T. A., & Gumbiner, B. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02774-1 · Cited by 495
Protease inhibitors and cardiovascular outcomes in patients with HIV-1
Holmberg, S. D., Moorman, A. C., Williamson, J. M., Tong, T. C., Ward, D. J., Wood, K. C., Greenberg, A. E., & Janssen, R. S. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11672-2 · Cited by 488
Ritonavir: Clinical Pharmacokinetics and Interactions with Other Anti-HIV Agents
Hsu, A., Granneman, G. R., & Bertz, R. J. (1998) · Clinical Pharmacokinetics · doi:10.2165/00003088-199835040-00002 · Cited by 483
Stein, J. H., Klein, M. A., Bellehumeur, J. L., McBride, P. E., Wiebe, D. A., Otvos, J. D., & Sosman, J. M. (2001) · Circulation · doi:10.1161/01.cir.104.3.257 · Cited by 479
Self-citationTsiodras, S., Mantzoros, C., Hammer, S., & Samore, M. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.13.2050 · Cited by 452
Cholesterol Reduction Yields Clinical Benefit: Impact of Statin Trials
Gould, A. L., Rossouw, J. E., Santanello, N. C., Heyse, J. F., & Furberg, C. D. (1998) · Circulation · doi:10.1161/01.cir.97.10.946 · Cited by 442
Klein, D., Hurley, L. B., Quesenberry, C. P., & Sidney, S. (2002) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200208150-00002 · Cited by 420
Neuvonen, P. J., Kantola, T., & Kivistö, K. T. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90165-5 · Cited by 406
Dujovne, C. A., Ettinger, M. P., McNeer, J. F., Lipka, L. J., LeBeaut, A. P., Suresh, R., Yang, B. O., & Veltri, E. P. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02798-4 · Cited by 391
Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects
Purnell, J. Q., Zambon, A., Knopp, R. H., Pizzuti, D. J., Achari, R., Leonard, J. M., Locke, C., & Brunzell, J. D. (2000) · AIDS · doi:10.1097/00002030-200001070-00006 · Cited by 387
Comparison of statins in hypertriglyceridemia
Stein, E. A., Lane, M., & Laskarzewski, P. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00041-1 · Cited by 386
Schambelan, M., Benson, C. A., Carr, A., Currier, J. S., Dubé, M. P., Gerber, J. G., Grinspoon, S. K., Grunfeld, C., Kotler, D. P., Mulligan, K., et al. (2002) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200211010-00001 · Cited by 379
Self-citationMetabolic effects of indinavir in healthy HIV-seronegative men
Noor, M. A., Lo, J. C., Mulligan, K., Schwarz, J.-M., Halvorsen, R. A., Schambelan, M., & Grunfeld, C. (2001) · AIDS · doi:10.1097/00002030-200105040-00001 · Cited by 350
Fichtenbaum, C. J., Gerber, J. G., Rosenkranz, S. L., Segal, Y., Aberg, J. A., Blaschke, T., Alston, B., Fang, F., Kosel, B., & Aweeka, F. (2002) · AIDS · doi:10.1097/00002030-200203080-00008 · Cited by 338
Self-citationHoyert, D. L., Arias, E., Smith, B. L., Murphy, S. L., & Kochanek, K. D. (2001) · PubMed · Cited by 338
Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study
Fellay, J., Ledergerber, B., Bernasconi, E., Furrer, H., Battegay, M., Hirschel, B., Vernazza, P., Francioli, P., Greub, G., Flepp, M., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06413-3 · Cited by 329
Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine
Martínez, E., Conget, I., Lozano, L., Casamitjana, R., & Gatell, J. M. (1999) · AIDS · doi:10.1097/00002030-199905070-00009 · Cited by 321
McKenney, J. M. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510330050033 · Cited by 306
Carr, A. (2002) · JAMA · doi:10.1001/jama.288.2.207 · Cited by 300
Circulating interferon-α levels and hypertriglyceridemia in the acquired immunodeficiency syndrome.
Grunfeld, C., Kotler, D. P., Shigenaga, J. K., Doerrler, W., Tierney, A., Wang, J., Pierson, R. N., & Feingold, K. R. (1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90536-7 · Cited by 286
Circulating interferon-α levels and hypertriglyceridemia in the acquired immunodeficiency syndrome
Grunfeld, C., Kotler, D. P., Shigenaga, J. K., Doerrler, W., Tierney, A., Wang, J., Pierson, R. N., & Feingold, K. R. (1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)80154-e · Cited by 286
Nicotinic Acid as Therapy for Dyslipidemia in Non—Insulin-Dependent Diabetes Mellitus
Garg, A. (1990) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1990.03450060069031 · Cited by 286
André, P., Groettrup, M., Klenerman, P., de Giuli, R., Booth, B. L., Cerundolo, V., Bonneville, M., Jotereau, F., Zinkernagel, R. M., & Lotteau, V. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.22.13120 · Cited by 279
Erickson, D. A., Mather, G., Trager, W. F., Levy, R. H., & Keirns, J. J. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)14960-4 · Cited by 277
Premature atherosclerosis in HIV-infected individuals – focus on protease inhibitor therapy
Depairon, M., Chessex, S., Sudre, P., Rodondi, N., Doser, N., Chave, J.-P., Riesen, W., Nicod, P., Darioli, R., Telenti, A., et al. (2001) · AIDS · doi:10.1097/00002030-200102160-00005 · Cited by 273
Liang, J.-S., Distler, O., Cooper, D. A., Jamil, H., Deckelbaum, R. J., Ginsberg, H. N., & Sturley, S. L. (2001) · Nature Medicine · doi:10.1038/nm1201-1327 · Cited by 261
van der Valk, M., Kastelein, J. J. P., Murphy, R. L., van Leth, F., Katlama, C., Horban, A., Glesby, M., Behrens, G., Clotet, B., Stellato, R. K., et al. (2001) · AIDS · doi:10.1097/00002030-200112070-00008 · Cited by 253
Self-citationIncreased de novo hepatic lipogenesis in human immunodeficiency virus infection
Hellerstein, M. K. (1993) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.76.3.559 · Cited by 245
Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors
Maggi, P., Serio, G., Epifani, G., Fiorentino, G., Saracino, A., Fico, C., Perilli, F., Lillo, A., Ferraro, S., Gargiulo, M., et al. (2000) · AIDS · doi:10.1097/00002030-200011100-00001 · Cited by 240
Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid
Neuvonen, P. J., & Jalava, K.-M. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90167-8 · Cited by 238
Murphy, R. L., Brun, S., Hicks, C., Eron, J. J., Gulick, R., King, M., White, A. C., Benson, C., Thompson, M., Kessler, H. A., et al. (2001) · AIDS · doi:10.1097/00002030-200101050-00002 · Cited by 238
Purpose of Quality Standards for Infectious Diseases
Gross, P. A., Barrett, T. L., Dellinger, E. P., Krause, P. J., Martone, W. J., McGowan, J. E., Sweet, R. L., & Wenzel, R. P. (1994) · Clinical Infectious Diseases · doi:10.1093/clinids/18.3.421 · Cited by 223
Christians, U., Jacobsen, W., & Floren, L. C. (1998) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00016-3 · Cited by 220
Disorders of Glucose Metabolism in Patients Infected with Human Immunodeficiency Virus
Dubé, M. P. (2000) · Clinical Infectious Diseases · doi:10.1086/317491 · Cited by 218
Self-citationRiddle, T. M., Kuhel, D. G., Woollett, L. A., Fichtenbaum, C. J., & Hui, D. Y. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104557200 · Cited by 216
Self-citationAtorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities
Henry, K., Melroe, H., Huebesch, J., Hermundson, J., & Simpson, J. (1998) · The Lancet · doi:10.1016/s0140-6736(98)00022-1 · Cited by 207
Shor-Posner, G., Basit, A., Lu, Y., Cabrejos, C., Chang, J., Fletcher, M., Mantero-Atienza, E., & Baum, M. K. (1993) · The American Journal of Medicine · doi:10.1016/0002-9343(93)90087-6 · Cited by 199
Clinical Pharmacokinetics of Non-Nucleoside Reverse Transcriptase Inhibitors
Smith, P. F., DiCenzo, R., & Morse, G. D. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140120-00002 · Cited by 198
Mayer, K. H., Dube, M. P., Sprecher, D., Henry, W. K., Aberg, J. A., Torriani, F. J., Hodis, H. N., Schouten, J., Levin, J., Myers, G., et al. (2000) · Clinical Infectious Diseases · doi:10.1086/317429 · Cited by 197
Self-citationFrost, P. H., & Havel, R. J. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00034-4 · Cited by 193
Feingold, K. R., Krauss, R. M., Pang, M., Doerrler, W., Jensen, P., & Grunfeld, C. (1993) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.76.6.8501146 · Cited by 183
Kahn, S. E., Beard, J. C., Schwartz, M. W., Ward, W. K., Ding, H. L., Bergman, R. N., Taborsky, G. J., & Porte, D. (1989) · Diabetes · doi:10.2337/diab.38.5.562 · Cited by 181
Ruiz, L., Negredo, E., Domingo, P., Paredes, R., Francia, E., Balagué, M., Gel, S., Bonjoch, A., Fumaz, C. R., Johnston, S., et al. (2001) · Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00042560-200107010-00003 · Cited by 174
Carr, A., Hudson, J., Chuah, J., Mallal, S., Law, M., Hoy, J., Doong, N., French, M., Smith, D., & Cooper, D. A. (2001) · AIDS · doi:10.1097/00002030-200109280-00010 · Cited by 172
Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin
Kivistö, K. T., Kantola, T., & Neuvonen, P. J. (1998) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1998.00034.x · Cited by 171
Ellen, R. L. B., & McPherson, R. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00040-x · Cited by 169
Fichtenbaum, C. J., & Gerber, J. G. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241140-00004 · Cited by 168
Self-citationKuhn, L., Coutsoudis, A., Moodley, D., Trabattoni, D., Mngqundaniso, N., Shearer, G. M., Clerici, M., Coovadia, H. M., & Stein, Z. (2001) · AIDS · doi:10.1097/00002030-200101050-00003 · Cited by 165
Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia
Wiklund, O., Angelin, B., Bergman, M., Berglund, L., Bondjers, G., Carlsson, A., Linden, T., Miettinen, T., Ödman, B., Olofsson, S.-O., et al. (1993) · The American Journal of Medicine · doi:10.1016/0002-9343(93)90114-5 · Cited by 165
Barreiro, P., Soriano, V., Blanco, F., Casimiro, C., Cruz, J. J. D. L., & González-Lahoz, J. (2000) · AIDS · doi:10.1097/00002030-200005050-00006 · Cited by 165
Rickerts, V., Brodt, H., Staszewski, S., & Stille, W. (2000) · PubMed · Cited by 149
Hadigan, C. M., Meigs, J. B., Rabe, J., D’Agostino, R. B., Wilson, P. W. F., Lipinska, I., Tofler, G. H., & Grinspoon, S. K. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7410 · Cited by 147
Serum Lipids and Incidence of Coronary Heart Disease
Frost, P. H., Davis, B. R., Burlando, A. J., Curb, J. D., Guthrie, G. P., Isaacsohn, J. L., Wassertheil-Smoller, S. W., Wilson, A. C., & Stamler, J. (1996) · Circulation · doi:10.1161/01.cir.94.10.2381 · Cited by 147
Clumeck, N., Goebel, F. D., Rozenbaum, W., Gerstoft, J., Staszewski, S., Montaner, J., Johnson, M. A., Gazzard, B., Stone, C., Athisegaran, R., et al. (2001) · AIDS · doi:10.1097/00002030-200108170-00009 · Cited by 144
Hsyu, P., Schultz-Smith, M. D., Lillibridge, J. H., Lewis, R. H., & Kerr, B. M. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.12.3445-3450.2001 · Cited by 144
Brown, B. G., Zhao-Q, X., Chait, A., & Fisher, L. D. (2002) · ACC Current Journal Review · doi:10.1016/s1062-1458(02)00657-8 · Cited by 144
HIV Protease Inhibitors Stimulate Hepatic Triglyceride Synthesis
Lenhard, J. M., Croom, D. K., Weiel, J. E., & Winegar, D. A. (2000) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.20.12.2625 · Cited by 138
Adkins, J. C., & Faulds, D. M. (1997) · Drugs · doi:10.2165/00003495-199754040-00007 · Cited by 137
Martínez, E., García-Viejo, M. A., Blanco, J. L., Bianchi, L., Buira, E., Conget, I., Casamitjana, R., Mallolas, J., & Gatell, J. M. (2000) · Clinical Infectious Diseases · doi:10.1086/317426 · Cited by 135
Yarasheski, K. E., Tebas, P., Stanerson, B. S., Claxton, S., Marin, D., Bae, K. T., Kennedy, M., Tantisiriwat, W., & Powderly, W. G. (2001) · Journal of Applied Physiology · doi:10.1152/jappl.2001.90.1.133 · Cited by 135
Dong, K. L., Bausserman, L., Flynn, M. M., Dickinson, B. P., Flanigan, T., Mileno, M. D., Tashima, K. T., & Carpenter, C. C. (1999) · PubMed · Cited by 133
Self-citationInhibition of Human Cytochrome P450 Isoforms by Nonnucleoside Reverse Transcriptase Inhibitors
Moltke, L. L., Greenblatt, D. J., Granda, B. W., Giancarlo, G. M., Duan, S. X., Daily, J. P., Harmatz, J. S., & Shader, R. I. (2001) · The Journal of Clinical Pharmacology · doi:10.1177/00912700122009728 · Cited by 127
Grady, D. G., Herrington, D. M., Bittner, V., Blumenthal, R. S., Davidson, M. H., Hlatky, M. A., Hsia, J. A., Hulley, S. B., Herd, A. J., Khan, S. S., et al. (2002) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-200210000-00020 · Cited by 124
Fauvel, J., Bonnet, É., Ruidavets, J., Ferrières, J., Toffoletti, A., Massip, P., Chap, H., & Perret, B. (2001) · AIDS · doi:10.1097/00002030-200112070-00007 · Cited by 120
Moyle, G. J., Lloyd, M., Reynolds, B., Baldwin, C., Mandalia, S., & Gazzard, B. (2001) · AIDS · doi:10.1097/00002030-200108170-00007 · Cited by 119
Jones, S. P., Doran, D. A., Leatt, P., Maher, B., & Pirmohamed, M. (2001) · AIDS · doi:10.1097/00002030-200110190-00021 · Cited by 117
Biotransformation of pravastatin sodium in humans.
Everett, D. W., Chando, T. J., DiDonato, G. C., Singhvi, S. M., Pan, H., & Weinstein, S. H. (1991) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08889-0 · Cited by 112
Dubé, M. P., Qian, D., Edmondson‐Melançon, H., Sattler, F. R., Goodwin, D., Martinez, C., Williams, V. C., Johnson, D., & Buchanan, T. A. (2002) · Clinical Infectious Diseases · doi:10.1086/341489 · Cited by 110
Self-citationMarked hyperlipidaemia on ritonavir therapy.
Sullivan, A., & Nelson, M. R. (1997) · PubMed · Cited by 108
Negredo, E., Ribalta, J., Paredes, R., Ferré, R., Sirera, G., Ruiz, L., Salazar, J., Reiss, P., Masana, L., & Clotet, B. (2002) · AIDS · doi:10.1097/00002030-200207050-00010 · Cited by 107
In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (±)-fluvastatin*
Transon, C., Leemann, T., Vogt, N., & Dayer, P. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90054-3 · Cited by 105
Mildvan, D., Wilets, I. F., Machado, S. G., & Grossberg, S. E. (1992) · The Lancet · doi:10.1016/0140-6736(92)91058-g · Cited by 101
Ischemic Cardiovascular Disease in Persons with Human Immunodeficiency Virus Infection
David, M. H., Hornung, R., & Fichtenbaum, C. J. (2002) · Clinical Infectious Diseases · doi:10.1086/324745 · Cited by 99
Self-citationHepatotoxicity associated with sustained-release niacin
Dalton, T. A., & Berry, R. S. (1992) · The American Journal of Medicine · doi:10.1016/0002-9343(92)90689-9 · Cited by 97
Antiretroviral therapy-associated hyperlipidaemia in HIV disease
Mooser, V., & Carr, A. (2001) · Current Opinion in Lipidology · doi:10.1097/00041433-200106000-00011 · Cited by 96
Miller, J., Brown, D., Amin, J., Kent-Hughes, J., Law, M. G., Kaldor, J. M., Cooper, D. A., & Carr, A. D. (2002) · AIDS · doi:10.1097/00002030-200211080-00012 · Cited by 96
Dubé, M. P., Edmondson‐Melançon, H., Qian, D., Aqeel, R., Johnson, D., & Buchanan, T. A. (2001) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200106010-00006 · Cited by 95
Self-citationMeng, Q., Lima, J. A. C., Lai, H. C., Vlahov, D., Celentano, D. D., Strathdee, S. A., Nelson, K. E., Wu, K. C., Chen, S., Tong, W., et al. (2002) · American Heart Journal · doi:10.1016/s0002-8703(02)00135-7 · Cited by 90
Davignon, J., Roederer, G., Montigny, M., Hayden, M. R., Tan, M.-H., Connelly, P., Hegele, R., McPherson, R., Lupien, P., Gagné, C., et al. (1994) · American Journal of Cardiology · doi:10.1016/0002-9149(94)90005-1 · Cited by 90
Fluvastatin with and without niacin for hypercholesterolemia
Jacobson, T. A., Chin, M. M., Fromell, G. J., Jokubaitis, L. A., & Amorosa, L. F. (1994) · The American Journal of Cardiology · doi:10.1016/0002-9149(94)90088-4 · Cited by 88
Hellerstein, M. K., Wu, K. K., McGrath, M. S., Faix, D. J., George, D., Shackleton, C. H. L., Horn, W. F., Hoh, R., & Neese, R. A. (1996) · Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology · doi:10.1097/00042560-199603010-00006 · Cited by 78
Grünfeld, C., & Feingold, K. R. (1992) · Journal of Nutrition · doi:10.1093/jn/122.suppl_3.749 · Cited by 71
Hyperlipidemia under treatment with proteinase inhibitors
Segerer, S., Bogner, J. R., Walli, R., Loch, O., & Goebel, F. D. (1999) · Infection · doi:10.1007/bf02560501 · Cited by 69
Van, J. T., Pan, J., Wasty, T., Chan, E., Wu, X., & Charles, M. A. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02333-0 · Cited by 55
Walli, R., Michl, G. M., Bogner, J. R., & Goebel, F.-D. (2001) · PubMed · Cited by 53
Baldini, F., Giambenedetto, S. D., Cingolani, A., Murri, R., Ammassari, A., & Luca, A. D. (2000) · AIDS · doi:10.1097/00002030-200007280-00025 · Cited by 48
Vyas, K. P., Kari, P. H., Pitzenberger, S. M., Halpin, R. A., Ramjit, H. G., Arison, B. H., Murphy, J. S., Hoffman, W. F., Schwartz, M. S., & Ulm, E. H. (1990) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)07606-8 · Cited by 47
Petit, J., Duong, M., Duvillard, L., Piroth, L., Grappin, M., Vergès, B. L., Chavanet, P., Brun, J. M., & Portier, H. (2000) · Hormone and Metabolic Research · doi:10.1055/s-2007-978655 · Cited by 42
Taher, T. H., Džavík, V., Reteff, E. M., Pearson, G. J., Woloschuk, B. L., & Francis, G. A. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)02258-5 · Cited by 41
Csako, G., McGriff, N. J., Rotman-Pikielny, P., Sarlis, N. J., & Pucino, F. (2001) · Annals of Pharmacotherapy · doi:10.1345/aph.1a031 · Cited by 40
Mastroianni, C. M., d’Ettorre, G., Forcina, G., Lichtner, M., Corpolongo, A., Coletta, S., & Vullo, V. (2001) · AIDS · doi:10.1097/00002030-200104130-00029 · Cited by 39
Vacek, J., Dittmeier, G., Chiarelli, T., White, J., & Bell, H. (1995) · American Journal of Cardiology · doi:10.1016/s0002-9149(99)80056-3 · Cited by 38
Palacios, R., Santos, J. S., González, M., Ruiz, J., Valdivielso, P., Márquez, M., & González‐Santos, P. (2002) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200208150-00012 · Cited by 37
Safety of combined pravastatin-gemfibrozil therapy
Rosenson, R. S., & Frauenheim, W. A. (1994) · The American Journal of Cardiology · doi:10.1016/0002-9149(94)90913-x · Cited by 36
Simvastatin-Induced Rhabdomyolysis in an HIV-Infected Patient with Coronary Artery Disease
Aboulafia, D. M., & Johnston, R. (2000) · AIDS Patient Care and STDs · doi:10.1089/108729100318091 · Cited by 35
Matthews, G. V., Moyle, G. J., Mandalia, S., Bower, M., Nelson, M. R., & Gazzard, B. (2000) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200008010-00002 · Cited by 30
Dubé, M. P., Edmondson‐Melançon, H., Qian, D., Aqeel, R., Johnson, D. L., & Buchanan, T. A. (2001) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00042560-200106010-00006 · Cited by 30
Self-citationDoser, N., Kübli, S., Telenti, A., Marzolini, C., Chave, J., Feihl, F., Buclin, T., Pannatier, A., Darioli, R., NICOD, P. H., et al. (2002) · AIDS · doi:10.1097/00002030-200209270-00024 · Cited by 29
Palacios, R., Santos, J., González, M., Ruiz, J., Valdivielso, P., Márquez, M., & González‐Santos, P. (2002) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200210010-00018 · Cited by 26
Lipid Abnormalities During Saquinavir Soft-Gel???Based Highly Active Antiretroviral Therapy
Moyle, G. J., & Baldwin, C. (2006) · Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology · doi:10.1097/01.pas.0000213299.11649.110 · Cited by 25
Effect of a Combination of Gemfibrozil and Niacin on Lipid Levels
Spencer, G. A., Wirebaugh, S. R., & Whitney, E. J. (1996) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1996.tb04237.x · Cited by 12
Lipid Abnormalities During Saquinavir Soft-Gel–Based Highly Active Antiretroviral Therapy
Moyle, G. J., & Baldwin, C. (1999) · Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology · doi:10.1097/00042560-199908150-00011 · Cited by 9
Cited by
Fihn, S. D., Gardin, J. M., Abrams, J., Berra, K., Blankenship, J. C., Dallas, A. P., Douglas, P. S., Foody, J. M., Gerber, T. C., Hinderliter, A. L., et al. (2012) · Circulation · doi:10.1161/cir.0b013e3182776f83 · Cited by 2,410
Virani, S. S., Newby, L. K., Arnold, S. V., Bittner, V., Brewer, L. C., Demeter, S. H., Dixon, D. L., Fearon, W. F., Hess, B., Johnson, H. M., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001168 · Cited by 1,598
Fihn, S. D., Gardin, J. M., Abrams, J., Berra, K., Blankenship, J. C., Dallas, A. P., Douglas, P. S., Foody, J. M., Gerber, T. C., Hinderliter, A. L., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.07.013 · Cited by 1,555
Fihn, S. D., Gardin, J. M., Abrams, J., Berra, K., Blankenship, J. C., Dallas, A. P., Douglas, P. S., Foody, J. M., Gerber, T. C., Hinderliter, A. L., et al. (2012) · Circulation · doi:10.1161/cir.0b013e318277d6a0 · Cited by 845
Aberg, J. A., Kaplan, J. E., Libman, H., Emmanuel, P., Anderson, J. R., Stone, V. E., Oleske, J. M., Currier, J. S., & Gallant, J. E. (2009) · Clinical Infectious Diseases · doi:10.1086/605292 · Cited by 837
Self-citation
Metadata
- Authors
- Dubé, M. P., Stein, J. H., Aberg, J. A., Fichtenbaum, C. J., Gerber, J. G., Tashima, K. T., Henry, W. K., Currier, J. S., Sprecher, D., Glesby, M. J., & Adult AIDS Clinical Trials Group Cardiovascular Subcommittee
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-09-01
- Volume
- 37
- Issue
- 5
- Pages
- 613-627
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2168784348
- Cited by
- 580
- References
- 129
- FWCI
- 45.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.